SC 404

Drug Profile

SC 404

Alternative Names: SC404

Latest Information Update: 22 Jan 2016

Price : $50

At a glance

  • Originator Sancilio & Company
  • Class
  • Mechanism of Action Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Primary sclerosing cholangitis

Most Recent Events

  • 22 Jan 2016 Preclinical trials in Primary sclerosing cholangitis in USA (unspecified route) before January 2016 (Sancilio pipeline; January 2015)
  • 01 Dec 2014 SC 404 receives Orphan Drug status for Primary sclerosing cholangitis in USA (Sancilio pipeline; January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top